STOCK TITAN

Citadel group reports 1.87M shares in Veradermics (MANE)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Veradermics, Incorporated ownership disclosure: Citadel Advisors LLC and related reporting persons report shared beneficial ownership of 1,870,775 shares of Common Stock. The filing states this position represents 4.5% of shares outstanding based on 41,183,254 Shares outstanding as of May 1, 2026.

The joint filing lists the reporting group (Citadel Advisors, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities entities and Kenneth Griffin) and details shared voting and dispositive power over the reported shares. Signature blocks show the statement was filed on behalf of the reporting persons.

Positive

  • None.

Negative

  • None.
Shares reported beneficially owned 1,870,775 shares Amount jointly reported by Citadel Advisors group
Percent of class 4.5% Calculated using 41,183,254 shares outstanding as of May 1, 2026
Shares outstanding (basis) 41,183,254 shares Shares outstanding as of May 1, 2026 per prospectus cited
Citadel Securities holdings shown 17 shares Beneficial ownership attributed to Citadel Securities LLC and related entities
Schedule 13G regulatory
"This statement is being jointly filed by Citadel Advisors LLC"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficial ownership regulatory
"Amount beneficially owned: 1. Each of Citadel Advisors LLC... may be deemed to beneficially own 1,870,775 Shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared dispositive power regulatory
"Shared Dispositive Power 1,870,775.00"
joint filing regulatory
"This is being jointly filed by Citadel Advisors LLC, Citadel Advisors Holdings LP... and Mr. Kenneth Griffin"





922967104

(CUSIP Number)
04/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 41,183,254 Shares outstanding as of May 1, 2026 (according to the issuer's prospectus as filed with the Securities and Exchange Commission on April 30, 2026). Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on May 7, 2026.


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Citadel Advisors LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:05/07/2026
Citadel Advisors Holdings LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:05/07/2026
Citadel GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:05/07/2026
Citadel Securities LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:05/07/2026
Citadel Securities Group LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:05/07/2026
Citadel Securities GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:05/07/2026
Kenneth Griffin
Signature:/s/ Seth Levy
Name/Title:Seth Levy, attorney-in-fact*
Date:05/07/2026

Comments accompanying signature: * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
Exhibit Information

Exhibit 99.1 - Joint Filing Agreement

FAQ

What stake does Citadel report in Veradermics (MANE)?

Citadel reports shared beneficial ownership of 1,870,775 shares, equal to 4.5% of the company's outstanding common stock as of May 1, 2026. The amount reflects holdings attributed to Citadel entities and Kenneth Griffin.

How was the 4.5% ownership percentage calculated?

The percentage is based on 41,183,254 Shares outstanding as of May 1, 2026, per the filing's cited prospectus on April 30, 2026. The filing ties the 4.5% figure to that outstanding share count.

Which Citadel entities are included in the joint filing?

The joint filing names Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC and Kenneth Griffin as the reporting persons.

What voting and dispositive powers are reported?

The filing states the reporting persons have 0 sole voting and 1,870,775 shared voting powers (Citadel Advisors group); Citadel Securities entities show 17 shared voting powers. Shared dispositive powers match the shared voting counts.

Does the filing claim beneficial ownership by each reporting person?

The filing explains certain entities may be deemed to beneficially own the reported shares and specifies relationships (portfolio manager, general partner, controlling interest). It disclaims that filing alone is not admission of beneficial ownership beyond actual holdings.